<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39408932</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Comprehensive Optimization of a Freeze-Drying Process Achieving Enhanced Long-Term Stability and In Vivo Performance of Lyophilized mRNA-LNPs.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10603</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms251910603</ELocationID><Abstract><AbstractText>The success of mRNA vaccines against SARS-CoV-2 has prompted interest in mRNA-based pharmaceuticals due to their rapid production, adaptability, and safety. Despite these advantages, the inherent instability of mRNA and its rapid degradation in vivo underscores the need for an encapsulation system for the administration and delivery of RNA-based therapeutics. Lipid nanoparticles (LNPs) have proven the most robust and safest option for in vivo applications. However, the mid- to long-term storage of mRNA-LNPs still requires sub-zero temperatures along the entire chain of supply, highlighting the need to develop alternatives to improve mRNA vaccine stability under non-freezing conditions to facilitate logistics and distribution. Lyophilization presents itself as an effective alternative to prolong the shelf life of mRNA vaccines under refrigeration conditions, although a complex optimization of the process parameters is needed to maintain the integrity of the mRNA-LNPs. Recent studies have demonstrated the feasibility of freeze-drying LNPs, showing that lyophilized mRNA-LNPs retain activity and stability. However, long-term functional data remain limited. Herein, we focus on obtaining an optimized lyophilizable mRNA-LNP formulation through the careful selection of an optimal buffer and cryoprotectant and by tuning freeze-drying parameters. The results demonstrate that our optimized lyophilization process maintains LNP characteristics and functionality for over a year at refrigerated temperatures, offering a viable solution to the logistical hurdles of mRNA vaccine distribution.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alejo</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9324-0446</Identifier><AffiliationInfo><Affiliation>CerTest Biotec S.L., 50840 San Mateo de Gállego, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toro-Córdova</LastName><ForeName>Alfonso</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0087-7780</Identifier><AffiliationInfo><Affiliation>CerTest Biotec S.L., 50840 San Mateo de Gállego, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernández</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CerTest Biotec S.L., 50840 San Mateo de Gállego, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivero</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CerTest Biotec S.L., 50840 San Mateo de Gállego, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stoian</LastName><ForeName>Andrei Mihai</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>CerTest Biotec S.L., 50840 San Mateo de Gállego, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pérez</LastName><ForeName>Luna</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CerTest Biotec S.L., 50840 San Mateo de Gállego, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navarro</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>CerTest Biotec S.L., 50840 San Mateo de Gállego, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez-Oliván</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CerTest Biotec S.L., 50840 San Mateo de Gállego, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Miguel</LastName><ForeName>Diego</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-8486-8514</Identifier><AffiliationInfo><Affiliation>CerTest Biotec S.L., 50840 San Mateo de Gállego, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>IDMF/2021/0009</GrantID><Agency>Gobierno de Aragón</Agency><Country /></Grant><Grant><GrantID>PTQ2021-011651</GrantID><Agency>Ministerio de Ciencia, Innovación y Universidades</Agency><Country /></Grant><Grant><GrantID>PTQ2022-012362</GrantID><Agency>Ministerio de Ciencia, Innovación y Universidades</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000711949">Lipid Nanoparticles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000087503">mRNA Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008081">Liposomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003451">Cryoprotective Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005612" MajorTopicYN="Y">Freeze Drying</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="Y">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020871" MajorTopicYN="N">RNA Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087503" MajorTopicYN="N">mRNA Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003451" MajorTopicYN="N">Cryoprotective Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">freeze-drying/lyophilization</Keyword><Keyword MajorTopicYN="N">mRNA-LNPs</Keyword><Keyword MajorTopicYN="N">thermostable vaccines</Keyword></KeywordList><CoiStatement>Teresa Alejo, Alfonso Toro, Laura Fernández, Andrea Rivero, Andrei Mihai, Luna Pérez, Victor Navarro, Juan Martínez, and Diego de Miguel are employees at the Certest Pharma Department, Certest Biotec S.L.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39408932</ArticleId><ArticleId IdType="pmc">PMC11476828</ArticleId><ArticleId IdType="doi">10.3390/ijms251910603</ArticleId><ArticleId IdType="pii">ijms251910603</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hogan M.J., Pardi N. mRNA Vaccines in the COVID-19 Pandemic and Beyond. Annu. Rev. Med. 2022;73:17–39. doi: 10.1146/annurev-med-042420-112725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-042420-112725</ArticleId><ArticleId IdType="pubmed">34669432</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabo G.T., Mahiny A.J., Vlatkovic I. COVID-19 mRNA vaccines: Platforms and current developments. Mol. Ther. 2022;30:1850–1868. doi: 10.1016/j.ymthe.2022.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2022.02.016</ArticleId><ArticleId IdType="pmc">PMC8856755</ArticleId><ArticleId IdType="pubmed">35189345</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenchov R., Bird R., Curtze A.E., Zhou Q. Lipid Nanoparticles horizontal line From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano. 2021;15:16982–17015. doi: 10.1021/acsnano.1c04996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.1c04996</ArticleId><ArticleId IdType="pubmed">34181394</ArticleId></ArticleIdList></Reference><Reference><Citation>Oude Blenke E., Örnskov E., Schöneich C., Nilsson G.A., Volkin D.B., Mastrobattista E., Almarsson Ö., Crommelin D.J.A. The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case. J. Pharm. Sci. 2023;112:386–403. doi: 10.1016/j.xphs.2022.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2022.11.001</ArticleId><ArticleId IdType="pmc">PMC9637289</ArticleId><ArticleId IdType="pubmed">36351479</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenmaker L., Witzigmann D., Kulkarni J.A., Verbeke R., Kersten G., Jiskoot W., Crommelin D.J. Mrna-Lipid Nanoparticle Covid-19 Vaccines: Structure and Stability. Int. J. Pharm. 2021;601:120586. doi: 10.1016/j.ijpharm.2021.120586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2021.120586</ArticleId><ArticleId IdType="pmc">PMC8032477</ArticleId><ArticleId IdType="pubmed">33839230</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou X., Zaks T., Langer R., Dong Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 2021;6:1078–1094. doi: 10.1038/s41578-021-00358-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41578-021-00358-0</ArticleId><ArticleId IdType="pmc">PMC8353930</ArticleId><ArticleId IdType="pubmed">34394960</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardeshi S.R., Deshmukh N.S., Telange D.R., Nangare S.N., Sonar Y.Y., Lakade S.H., Harde M.T., Pardeshi C.V., Gholap A., Deshmukh P.K., et al. Process development and quality attributes for the freeze-drying process in pharmaceuticals, biopharmaceuticals and nanomedicine delivery: A state-of-the-art review. Future J. Pharm. Sci. 2023;9:99. doi: 10.1186/s43094-023-00551-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43094-023-00551-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatto M.S., Najahi-Missaoui W. Lyophilization of Nanoparticles, Does It Really Work? Overview of the Current Status and Challenges. Int. J. Mol. Sci. 2023;24:14041. doi: 10.3390/ijms241814041.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241814041</ArticleId><ArticleId IdType="pmc">PMC10530935</ArticleId><ArticleId IdType="pubmed">37762348</ArticleId></ArticleIdList></Reference><Reference><Citation>Trenkenschuh E., Friess W. Freeze-drying of nanoparticles: How to overcome colloidal instability by formulation and process optimization. Eur. J. Pharm. Biopharm. 2021;165:345–360. doi: 10.1016/j.ejpb.2021.05.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2021.05.024</ArticleId><ArticleId IdType="pubmed">34052428</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao P., Hou X., Yan J., Du S., Xue Y., Li W., Xiang G., Dong Y. Long-term storage of lipid-like nanoparticles for mRNA delivery. Bioact. Mater. 2020;5:358–363. doi: 10.1016/j.bioactmat.2020.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioactmat.2020.03.001</ArticleId><ArticleId IdType="pmc">PMC7078456</ArticleId><ArticleId IdType="pubmed">32206737</ArticleId></ArticleIdList></Reference><Reference><Citation>Muramatsu H., Lam K., Bajusz C., Laczko D., Kariko K., Schreiner P., Martin A., Lutwyche P., Heyes J., Pardi N. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine. Mol. Ther. 2022;30:1941–1951. doi: 10.1016/j.ymthe.2022.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2022.02.001</ArticleId><ArticleId IdType="pmc">PMC8815268</ArticleId><ArticleId IdType="pubmed">35131437</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai L., Li Y., Zhou L., Yao W., Zhang H., Hu Z., Han J., Wang W., Wu J., Xu P., et al. Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2. Cell Discov. 2023;9:9. doi: 10.1038/s41421-022-00517-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-022-00517-9</ArticleId><ArticleId IdType="pmc">PMC9868121</ArticleId><ArticleId IdType="pubmed">36683074</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki Y., Miyazaki T., Muto H., Kubara K., Mukai Y., Watari R., Sato S., Kondo K., Tsukumo S.I., Yasutomo K., et al. Design and lyophilization of lipid nanoparticles for mRNA vaccine and its robust immune response in mice and nonhuman primates. Mol. Ther. Nucleic Acids. 2022;30:226–240. doi: 10.1016/j.omtn.2022.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2022.09.017</ArticleId><ArticleId IdType="pmc">PMC9508692</ArticleId><ArticleId IdType="pubmed">36187052</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbeke R., Lentacker I., De Smedt S.C., Dewitte H. The dawn of mRNA vaccines: The COVID-19 case. J. Control. Release. 2021;333:511–520. doi: 10.1016/j.jconrel.2021.03.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2021.03.043</ArticleId><ArticleId IdType="pmc">PMC8008785</ArticleId><ArticleId IdType="pubmed">33798667</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung H.N., Lee S.Y., Lee S., Youn H., Im H.J. Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging. Theranostics. 2022;12:7509–7531. doi: 10.7150/thno.77259.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.77259</ArticleId><ArticleId IdType="pmc">PMC9691360</ArticleId><ArticleId IdType="pubmed">36438494</ArticleId></ArticleIdList></Reference><Reference><Citation>Hald Albertsen C., Kulkarni J.A., Witzigmann D., Lind M., Petersson K., Simonsen J.B. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv. Drug Deliv. Rev. 2022;188:114416. doi: 10.1016/j.addr.2022.114416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2022.114416</ArticleId><ArticleId IdType="pmc">PMC9250827</ArticleId><ArticleId IdType="pubmed">35787388</ArticleId></ArticleIdList></Reference><Reference><Citation>Meulewaeter S., Nuytten G., Cheng M.H.Y., De Smedt S.C., Cullis P.R., De Beer T., Lentacker I., Verbeke R. Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures. J. Control. Release. 2023;357:149–160. doi: 10.1016/j.jconrel.2023.03.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2023.03.039</ArticleId><ArticleId IdType="pmc">PMC10062427</ArticleId><ArticleId IdType="pubmed">36958400</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson M.I., Eygeris Y., Jozic A., Herrera M., Sahay G. Leveraging Biological Buffers for Efficient Messenger RNA Delivery via Lipid Nanoparticles. Mol. Pharm. 2022;19:4275–4285. doi: 10.1021/acs.molpharmaceut.2c00587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.molpharmaceut.2c00587</ArticleId><ArticleId IdType="pmc">PMC9916253</ArticleId><ArticleId IdType="pubmed">36129254</ArticleId></ArticleIdList></Reference><Reference><Citation>Packer M., Gyawali D., Yerabolu R., Schariter J., White P. A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems. Nat. Commun. 2021;12:6777. doi: 10.1038/s41467-021-26926-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26926-0</ArticleId><ArticleId IdType="pmc">PMC8608879</ArticleId><ArticleId IdType="pubmed">34811367</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorat A.A., Suryanarayanan R. Characterization of Phosphate Buffered Saline (PBS) in Frozen State and after Freeze-Drying. Pharm. Res. 2019;36:98. doi: 10.1007/s11095-019-2619-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-019-2619-2</ArticleId><ArticleId IdType="pubmed">31087169</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelwahed W., Degobert G., Stainmesse S., Fessi H. Freeze-drying of nanoparticles: Formulation, process and storage considerations. Adv. Drug Deliv. Rev. 2006;58:1688–1713. doi: 10.1016/j.addr.2006.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2006.09.017</ArticleId><ArticleId IdType="pubmed">17118485</ArticleId></ArticleIdList></Reference><Reference><Citation>Degobert G., Aydin D. Lyophilization of Nanocapsules: Instability Sources, Formulation and Process Parameters. Pharmaceutics. 2021;13:1112. doi: 10.3390/pharmaceutics13081112.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics13081112</ArticleId><ArticleId IdType="pmc">PMC8400524</ArticleId><ArticleId IdType="pubmed">34452072</ArticleId></ArticleIdList></Reference><Reference><Citation>Kafetzis K.N., Papalamprou N., McNulty E., Thong K.X., Sato Y., Mironov A., Purohit A., Welsby P.J., Harashima H., Yu-Wai-Man C., et al. The Effect of Cryoprotectants and Storage Conditions on the Transfection Efficiency, Stability, and Safety of Lipid-Based Nanoparticles for mRNA and DNA Delivery. Adv. Healthc. Mater. 2023;12:e2203022. doi: 10.1002/adhm.202203022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adhm.202203022</ArticleId><ArticleId IdType="pmc">PMC11468535</ArticleId><ArticleId IdType="pubmed">36906918</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakubek Z.J., Chen S., Zaifman J., Tam Y.Y.C., Zou S. Lipid Nanoparticle and Liposome Reference Materials: Assessment of Size Homogeneity and Long-Term -70 degrees C and 4 degrees C Storage Stability. Langmuir. 2023;39:2509–2519. doi: 10.1021/acs.langmuir.2c02657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.langmuir.2c02657</ArticleId><ArticleId IdType="pmc">PMC9948293</ArticleId><ArticleId IdType="pubmed">36748988</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung A.K., Hafez I.M., Baoukina S., Belliveau N.M., Zhigaltsev I.V., Afshinmanesh E., Tieleman D.P., Hansen C.L., Hope M.J., Cullis P.R. Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core. J. Phys. Chem. C Nanomater. Interfaces. 2012;116:18440–18450. doi: 10.1021/jp303267y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jp303267y</ArticleId><ArticleId IdType="pmc">PMC3434764</ArticleId><ArticleId IdType="pubmed">22962627</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung A.K.K., Tam Y.Y.C., Chen S., Hafez I.M., Cullis P.R. Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems. J. Phys. Chem. B. 2015;119:8698–8706. doi: 10.1021/acs.jpcb.5b02891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jpcb.5b02891</ArticleId><ArticleId IdType="pubmed">26087393</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng M.H.Y., Leung J., Zhang Y., Strong C., Basha G., Momeni A., Chen Y., Jan E., Abdolahzadeh A., Wang X., et al. Induction of Bleb Structures in Lipid Nanoparticle Formulations of mRNA Leads to Improved Transfection Potency. Adv. Mater. 2023;35:2303370. doi: 10.1002/adma.202303370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.202303370</ArticleId><ArticleId IdType="pubmed">37172950</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez J., Lampaya V., Larraga A., Magallon H., Casabona D. Purification of linearized template plasmid DNA decreases double-stranded RNA formation during IVT reaction. Front. Mol. Biosci. 2023;10:1248511. doi: 10.3389/fmolb.2023.1248511.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2023.1248511</ArticleId><ArticleId IdType="pmc">PMC10570549</ArticleId><ArticleId IdType="pubmed">37842641</ArticleId></ArticleIdList></Reference><Reference><Citation>Masotti A., Preckel T. Analysis of small RNAs with the Agilent 2100 Bioanalyzer. Nat. Methods. 2006;3:658. doi: 10.1038/nmeth908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth908</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>